-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $101

Benzinga·10/28/2026 17:26:59
Listen to the news
Goldman Sachs analyst Paul Choi maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $90 to $101.